July 23, 2025

FDA Grants Breakthrough Status to Melanoma Test

The FDA has granted Breakthrough Device designation to Castle Biosciences’ DecisionDx-Melanoma test, a gene expression profile assay designed to improve risk stratification and personalized care in cutaneous melanoma.

Conexiant

July 23, 2025

Ultrasound Combo Detects MASH and Fibrosis

Two ultrasound techniques show strong diagnostic performance for steatohepatitis and fibrosis, supporting a noninvasive alternative to biopsy.

Conexiant

July 22, 2025

Placenta Accreta Guidelines Lack Consensus: Review

A new review of clinical guidelines highlights consistent recommendations for diagnosing and managing placenta accreta spectrum disorders, but showed gaps in guidance for surgery, fertility counseling, and postnatal care, especially in low-resource settings.

Conexiant

July 22, 2025

Might That Lip Lesion Be BCC?

New research has documented 4 cases of lip basal cell carcinoma presenting as smooth yellow nodules—a rare clinical presentation that may be mistaken for benign mesenchymal tumors, potentially resulting in diagnostic delays and postponed treatment.

Conexiant

July 14, 2025

GLP-1 Use Tied to Reflux Complications

Researchers found that GLP-1 receptor agonists were associated with an increased risk of GERD and related complications in patients with type 2 diabetes.

Conexiant

July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

May 22, 2025

At-Home HPV Test Matches Clinic Accuracy

Researchers found that an at-home self-collection device for HPV testing demonstrated high accuracy and safety, matching clinician-collected results for cervical cancer screening.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant